Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calithera Biosciences Inc.

www.calithera.com

Latest From Calithera Biosciences Inc.

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Financing Business Strategies

Calithera’s Telaglenastat Doubles PFS In Proof-Of-Concept Study

The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.

Clinical Trials Companies

Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Pipeline Watch: Kisqali, SI-6603, Cosentyx Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Respiratory, Pulmonary
  • Alias(es)
  • Protein Activation Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Calithera Biosciences Inc.
  • Senior Management
  • Susan M Molineaux, PhD, Pres. & CEO
    Curtis Hecht, CBO
    Stephanie Wong, SVP, Fin.
    Keith Orford, MD, PhD, CMO
  • Contact Info
  • Calithera Biosciences Inc.
    Phone: (650) 870-1000
    343 Oyster Point Blvd.
    Ste. 200
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register